ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Biogen Inc

Biogen Inc (1BIIB)

214.50
0.00
(0.00%)
Closed July 09 11:30AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
214.50
Bid
208.40
Ask
216.00
Volume
0.00
0.00 Day's Range 0.00
177.65 52 Week Range 244.60
Market Cap
Previous Close
214.50
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
35
Shares Outstanding
145,596,895
Dividend Yield
-
PE Ratio
28.60
Earnings Per Share (EPS)
7.97
Revenue
9.84B
Net Profit
1.16B

About Biogen Inc

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Italian Stock Exchange with ticker 1BIIB. The last closing price for Biogen was 214.50 €. Over the last year, Biogen shares have traded in a share price range of 177.65 € to 244.60 €.

Biogen currently has 145,596,895 shares outstanding. The market capitalization of Biogen is 31.23 € billion. Biogen has a price to earnings ratio (PE ratio) of 28.60.

1BIIB Latest News

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology...

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China China is the Third Country to Launch LEQEMBI Following the United States and JapanTOKYO and CAMBRIDGE, Mass...

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by Biogen...

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease TOKYO and...

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic...

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Transaction to include felzartamab, a potential first-in-class...

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Development of BIIB105, an investigational antisense oligonucleotide for...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.5-2.05479452055219219212.268215.49264706DE
41.20.56258790436213.3219206.145212.75261845DE
1230.116.3232104121184.4219177.6535203.2667978DE
26-22.3-9.41722972973236.8244.6177.6532206.33642399DE
52-1.1-0.510204081633215.6244.6177.6530207.66392625DE
156-1.1-0.510204081633215.6244.6177.6530207.66392625DE
260-1.1-0.510204081633215.6244.6177.6530207.66392625DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SHPWShapeways Holdings Inc
$ 0.5041
(140.05%)
92.14M
ZAPPZapp Electric Vehicles Group Ltd
$ 9.25
(127.27%)
105.05M
IVPInspire Veterinary Partners Inc
$ 2.94
(97.32%)
54.79M
VRPXVirpax Pharmaceuticals Inc
$ 1.10
(90.31%)
161.22M
MORFMorphic Holding Inc
$ 55.71
(74.97%)
53.24M
HLVXHilleVax Inc
$ 1.63
(-88.41%)
25.64M
CLEUChina Liberal Education Holdings Ltd
$ 0.568999
(-73.90%)
15.69M
SYTSYLA Technologies Company Ltd
$ 2.07
(-31.91%)
534.24k
CJETChijet Motor Company Inc
$ 6.00
(-25.93%)
188.91k
WETHWetouch Technology Inc
$ 2.44
(-22.78%)
518.66k
MAXNMaxeon Solar Technologies Ltd
$ 0.2722
(13.42%)
493.51M
NVDANVIDIA Corporation
$ 128.20
(1.88%)
237.67M
VRPXVirpax Pharmaceuticals Inc
$ 1.10
(90.31%)
161.22M
TSLATesla Inc
$ 252.94
(0.56%)
157.27M
SVMHSRIVARU Holding Ltd
$ 0.1874
(17.94%)
121.48M

Discussion

View Full Feed
kayak_wench kayak_wench 3 minutes ago
Recall that the IDE Vivos submitted is for an Early Feasibility Medical Device Clinical Study (EFS). Submitting an an EFS was the FDAs recommendation to the company. The EFS Program is open to devices subject to Premarket Approval (PMA), Premarket Notification (510[k]), De Novo classification, or
RDGL
DMC8 DMC8 3 minutes ago
https://ca.finance.yahoo.com/news/lilly-agrees-buy-us-biotech-110605998.html
AMRN
Prestotic Prestotic 4 minutes ago
And please tell me who is deleting my post here Mr moderator. Does an alternate opinion bother you or interupt your plans that much. Leads me to believe that Nebraska and Alaska are correct in their P & D theories.
VXIT
Chiugray Chiugray 6 minutes ago
Norisknorewards, That says it all. “This guy works for citadel”

The story of NWBO’s journey battling a wolfpack of market manipulators, short minions, naked shorting, spoofing orders, marking-the-closing price, frivolous lawsuits, fake journalists, fake stories, daily FUD postings, ar
NWBO
SF971 SF971 8 minutes ago
Near-term strategy is a Nasdaq uplist.

CEO has always envisioned "ringing the bell" as one of his life-long goals.

Question is how quickly they get there as they already have the revenues to support an uplist.
YCRM
georgejjl georgejjl 9 minutes ago
Suddenly, there's talk of 3 rate cuts this year

3 interest rate cuts would be very good for the US and world economies. Also, very good for AVXL stock.

https://finance.yahoo.com/news/suddenly-theres-talk-3-rate-024500987.html

Good luck and GOD bless,
AVXL
SF971 SF971 10 minutes ago
Was anyone here in $GDVM?

Another cybersecurity company reverse merger with near identical OS to $YCRM.

A handful of whales led by John Kent locked up the float and walked it up from sub-pennies to .13+ in 6 months.

Very retail friendly chart and almost e
GDVM YCRM
Foodman1291 Foodman1291 11 minutes ago
Dear Zena

Good luck with your new neurologist. She sounds like a keeper….

Stay well

Foodman
AVXL
SF971 SF971 11 minutes ago
Unlike their other paid promo pumps, they’ve put a muzzle on the CEO and influencers as well (for now).
YCRM
Iwasbornpoor Iwasbornpoor 13 minutes ago
I rest my case.
PLPL
Prestotic Prestotic 13 minutes ago
Neither do you, or I apparently. However, contrary to your statement, the guys on the VXIT team have been sleeping for over two years. Pandemic long gone, even with rising hospitalizations and new variants. Statements about effectiveness of a product, or launching a new website are not enough. VXIT
VXIT
Termite7 Termite7 15 minutes ago
I guess it went higher......for now!!!
ETHUSD
NanoEE NanoEE 16 minutes ago
https://electrek.co/2024/07/08/sk-on-is-working-on-3d-printing-ev-batteries-with-sakuu/

That is the lithium version.

The one Sandy is holding up that is Black in a plastic pouch is the Non -Metal Battery. That’s the one we need the specs on.
XenaLives XenaLives 16 minutes ago
Yeah - Schwab Sux Big Time...

SSXBT

The turmoil caused by transfer of retail accounts alone gave connected institutions a HUGE advantage.
AVXL
Lakota-45 Lakota-45 19 minutes ago
Excellent Summary 'Hawk' - Thanks for chiming in !!!

~ Just thinking; The Patient Longs & New Investors are going to be
"Happy Campers" in the not-so-distant-future !!!

~ $WDLF / Decentral Life ~
WDLF
Bob Mullet Bob Mullet 19 minutes ago
SCALING UP IS THE NEW SLAM DUNK AF
SCALING UP IS THE NEW SLAM DUNK AF SCALING UP IS THE NEW SLAM DUNK AF
SCALING UP IS THE NEW SLAM DUNK AF
SCALING UP IS THE NEW SLAM DUNK AF
SCALING UP IS THE NEW SLAM DUNK AF
SCALING UP IS THE NEW SLAM DUNK AF
SCALING UP IS
KBLB
DTGoody DTGoody 19 minutes ago
EXACTLY!!! I have ignored the noise! There is way too much going on here to be on the sidelines. If this goes expert market it will only be temporary. I know when it comes off it will be multi-pennies or multi-silver.
RSPI
Bob Mullet Bob Mullet 22 minutes ago
Do you give more a siht about

Scaling up
Doubling up
Ramping up OR
Expanding up…..production??

KBLB
CanItBThisEZ2Make CanItBThisEZ2Make 22 minutes ago
BEST SELLERS RANK (BSR) IS 709 5 Estimated Sold on Amazon Since JULY 1 - 3RD Quarter 2024
https://investorshub.advfn.com/uimage/uploads/2024/4/24/cnxttVOS_5G_GIF.gif
https://www.amazon.com/Vos-RDGL5GX55-B-01-VOS-5G-Dongle/dp/B0C66KHZLP

NOTE: In theory, when BSR Value Dec
SRMX
TradingCharts TradingCharts 22 minutes ago
I thought they were graphene but it is Li-metal

Sakuu's Dry-Printed Li-metal Batteries Hit 1,000 Cycles

40,889 views Jun 28, 2024 #sakuu #evbatteries
Sandy and the Munro Live Crew Visit Sakuu for an Update on Their Fully Dry Manufacturing Process, Featuring
BCM18 BCM18 23 minutes ago
BLLB is doing what is does as it usually does. Ya know....filing and staying current. Pd got cut to 3 posts a day so he broke out another accnt he been saving for the one stock that gave him trouble. Cmon let's see this 100x they/them claim to be able to pull off.
I'm READY!
BLLB
DTGoody DTGoody 24 minutes ago
Exhibit 10.2





NIH SERVICE AGREEMENT



(2)











Contents



1. PROVIDER OBLIGATIONS 3
2. FEES
RSPI
Slim6 Slim6 26 minutes ago
For the quarter Jan-Mar 2023, POET had net loss of $5.27 million.
For the quarter, Jan-Mar 2024, POET had net loss of $5.72 million. Those are both huge losses compared to the company's total revenue.
That is an increase of $450K. These losses are accumulating. POET just increased the
POET
Bob Mullet Bob Mullet 26 minutes ago
So, what you are saying is the news caused massive volume and share price spike??!?
KBLB
modes948 modes948 26 minutes ago
Yes hope so.Nice mail anyway.
HERB

Your Recent History

Delayed Upgrade Clock